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Objective: To investigate the antihistamine-releasing effect of a peptide isolated from
wasp venom of Vespa orientalis.
Methods: This peptide was separated from crude venom by chromatography methods
and mass spectrometry. Then various concentrations (2, 4, 8, 16, 32, 64, 128 and
256 mmol/L) of the peptide were incubated with mast cells and lactate dehydrogenase
assay was performed.
Results: No signiﬁcant effect was observed in lactate dehydrogenase absorbance under
128 mmol/L concentration. This implied that the peptide did not cause cell death in mast
cells and consequently, histamine release did not happen. Moreover, the results showed
the IC50 of mast cells degranulation at 126 mmol/L, which was approximately high
implying that this peptide had high selectivity for normal cells and did not cause hista-
mine release from these cells.
Conclusions: This would be a great aim in new drug development, in which an agent
acts potentially on its target tissue without activating the immune system.1. Introduction
Mast cells are the most important effector cells in inﬂam-
matory and allergic diseases [1]. Thus, researchers concerning
mast cells should focus on their detrimental pathologic effects.
However, mast cells play important roles in homeostasis and
may have a signiﬁcant function in defense against parasitic
and bacterial infections, the healing of wounds, and
participating in innate and adaptive immunity [2]. Mast cells
are the initial storage location of histamine in mammalian
tissues and placed in secretory granules [3]. These granules in
rats contain serotonin and a highly charged matrix of heparin
and protein which is released along with histamine [4].
Preventing mast cell degranulation is critically important indrug administration since immune system activation would
have destructive effect not only on exogenous particles, but
also may affect all body cells. Both inﬂammatory and anti-
inﬂammatory responses against several venoms, especially bee
venom, have been shown in many studies [5,6]. In this study, the
attempt was aimed to elucidate the antihistamine-releasing
activity of a speciﬁc peptide derived from wasp venom of
Vespa orientalis (V. orientalis).
2. Materials and methods
2.1. Venom extraction
V. orientalis specimens were collected from Abarkooh
located in central part of Iran. The dissected wasp's venom
glands were paralyzed at 4 C and then immersed in liquid ni-
trogen. By using pestle and liquid nitrogen, the glands were
crushed into a clean mortar. About 20 mL of 0.1 mol/L phos-
phate buffer (pH = 7.4) was added to the powdered samples
following liquid nitrogen evaporation. After centrifugation at
1500 r/min at 4 C for 15 min, the supernatant was siphoned to
another clean tube and further homogenized. Subsequently, the
tube content was lyophilized and kept at −20 C till it was
analyzed for further assay.under the CC BY-NC-ND license (http://
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The methodology described above produced a partially pu-
riﬁed extract of the venom. The extract was subjected to other
puriﬁcation steps, the most frequently of which are chromatog-
raphy procedures and mass spectrometry. The selection of one or
other (or both) depends on the knowledge of the peptide
characteristics.
2.3. Ion exchange chromatography
Venom (20 mg/mL) sample was dissolved in distilled water
after lyophilization, then it was loaded onto a fast protein liquid
chromatography system on a HiTrap™ SPHP (Sweden) cation
exchange column equilibrated with 30 mmol/L sodium bicar-
bonate buffer (pH 7.2). Venom was eluted with a linear gradient
of elution buffer 0.01 mol/L NaCl in the same buffer and the
ﬂow rate was 2 mL/min [7]. At a rate of 4 mL/min, fractions were
collected and monitored at 220 nm. The antihistamine-releasing
activities of the pooled fractions were investigated. In addition,
the active fractions were lyophilized and subjected to further
analysis.
2.4. Gel ﬁltration chromatography
After cation exchange chromatography, the collected active
fraction of peptide was dissolved in distilled water and loaded
onto a column (1 cm × 25 cm) of Sephadex G-25 gel ﬁltration
which was initially balanced with distilled water [8]. The column
was eluted with distilled water at a ﬂow rate of 60 mL/h followed
by collecting each fraction at a volume of 2 mL and its absorbance
wasmonitored at 220 nm by spectrophotometry, and each fraction
illustrating antihistamine-releasing activities was pooled, lyoph-
ilized and kept for next steps.
2.5. Reverse phase high performance liquid
chromatography (RP-HPLC)
Peptide detection was done by using a Knauer HPLC system.
Peptide aliquots (20 mL) were detected by a Vertex plus C18
column (250 mm × 4.6 mm) balanced with acidiﬁed water
[0.05% triﬂuoroacetic acid (TFA)]. The acidiﬁed water was used
for column washing for 5 min. Elution was then proceeded with
a linear gradient of 20%–80% acetonitrile in acidiﬁed water
(0.05% TFA) over 60 min at a ﬂow rate of 1 mL/min. Fractions
were collected into 3 mL volumes. The puriﬁcation of the ﬁnal
fraction was proceeded using the Smart HPLC (Amersham
Pharmacia Biotech) system equipped with a Sephasil peptide
C18 column (4.6 mm × 250 mm, Amersham Pharmacia
Biotech). Fraction elution was done with acidiﬁed water
(0.05% TFA in water) for 7 min, a linear gradient of 0%–60%
solvent D (0.05% TFA in acrylonitrile) for 20 min and ﬁnally
with 60%–100% solvent D for 1 min completed the elution
process. The detection wave length was set at 220 nm in which
the ﬂow rate was 0.1 mL/min [9].
2.6. Mass spectrometry
Electrospray ionization spectra were recorded using a Quattro
II triple quadrupole mass spectrometer (Micromass) ﬁxed with
an electrospray source. On-line liquid chromatography-massspectrometry1 was implemented using the 2nd step separation
procedure (C2/C18 column). A post-column split of nearly 10:1
(fraction collector and electrospray ionization mass spectrom-
eter) was used to enable similar fractionation and mass deter-
mination. Two alternating scan functions were employed as
follows: one at a sampling cone potential of 35 V to give the
molecular weight of the peptides and a second scan at a sam-
pling cone potential of 100 V to produce low mass fragment ions
to enable the determination of any post-translational variation,
such as glycosylation. The primary UV wave length of the Smart
system was also noted by the data system of the mass spec-
trometer so that the UV and total ion chromatogram outputs
were aligned [10].
2.7. Mast cell preparation
Mast cells were isolated from peritoneal area of adult female
Wistar rats weighing 300–350 g by using Kurosawa and Parker
modiﬁed method [11]. Firstly, 10 mL of cold Hank's balanced
salt solution was injected intraperitoneally and then the
abdomen was softly massaged for 2 min. The suspension was
aspirated and centrifuged at 2500 r/min at 4 C for 5 min.
Based on Hachisuka et al. method, mast cells were puriﬁed by
percoll density centrifugation [12]. Twice washing with Hank's
balanced salt solution containing 1 mg/mL bovine serum
albumin was done on puriﬁed mast cells.
2.8. Mast cell degranulation
The release of b-D-glucosaminidase was measured to deter-
mine the mast cell degranulation co-localized with histamine
[13]. Different concentrations (2, 4, 8, 16, 32, 64, 128 and
256 mmol/L) of peptide were incubated with mast cells at
37 C for 15 min. The tubes were centrifuged and then
supernatants were sampled for D-glucosaminidase assay.
Brieﬂy, 50 mL of each sample was incubated in 50 mL of the
substrate (3 mg of p-nitrophenyl-N-acetyl-b-D-glucosaminidine
dissolved in 10 mL of 0.2 mol/L sodium citrate solution at pH
4.5) overnight at 37 C. The absorbance of the colored
product was assessed at 405 nm and the values were
expressed as the percentage of total b-D-glucosaminidase
activity from rat mast cell suspensions, characteristic in lysed
mast cells in the presence of 0.1% (v/v) Triton X-100 [14].
2.9. Lactate dehydrogenase (LDH) assay
Various concentrations (2, 4, 8, 16, 32, 64, 128 and
256 mmol/L) of peptide were incubated with mast cells for 24 h.
The medium was removed without damaging cells for LDH
assay. Brieﬂy, 100 mL of each well medium was transferred to a
new plate and 100 mL of LDH catalyst and reagent (45:1)
(Roche cytotoxicity detection, Germany) was added to the su-
pernatant and incubated for 30 min in dark at room temperature.
Diaphorase and aldehyde dehydrogenase as a blue compound,
and iodo tetrazolium chloride plus sodium lactate as a red one
were urgent need to make LDH media (11/125 mmol/L of red
and 0/25 mmol/L of blue). The absorbance was recorded at
490 nm using an ELISA reader. Aliquot of 100 mL of 2% Triton
X-100 was added to the untreated cells considered as a high
control and media with cells as a low control. Cytotoxicity was
correlated with the percentage of LDH release [15].
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3. Results
3.1. Ion exchange chromatography
Fast protein liquid chromatography peptide detection results
indicated three clear fractions at 280 nm (Figure 1). The third
fraction showed antihistamine-releasing activity (Figure 2). ThisMT 2013May 
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Figure 1. V. orientalis venom detection result on exchange cationic col-
umn HiTrap™ in equivalent with 300 mmol/L bicarbonate and salt
gradient.
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Figure 2. Fast protein liquid chromatography and gel ﬁltration chromatographfraction was located in a 100 salt gradient region reﬂecting its
net positive charge. Its tight junction with column required more
buffer salt for separation. Additionally, the concentration of third
fraction was increased after ﬁltration with Millipore tubes and
peptides with molecular weight of 5000 Da and more were
passed.
3.2. Gel ﬁltration chromatography
Resin G-25 Sephadex was used in this assay that diameter
was 8–20 mm and separated salt and peptide. Results of gel
ﬁltration chromatography were shown in Figure 3.
3.3. RP-HPLC
The chromatogram of V. orientalis venom illustrated more
than 100 different agents and 20 high picks were shown in
Figure 4. RP-HPLC analysis eluted two picks, named formin
homology-1 (FH-1) and FH-2.
Following further analytical RP-HPLC analysis of samples
from each of these fractions, a histamine-releasing peptide of
novel primary structure was found in the fraction FH-1, there-
fore, this was further puriﬁed (Figure 5).
The primary structure of this novel peptide was established
by using tandem mass spectrometry fragmentation (Table 1).
3.4. Cytotoxic activity
The cytotoxic activity of the peptide was examined on mast
cells by LDH assay. LDH was an enzyme present in all cells and
was released in culture medium after cell death. In this assay,
NADH/H+ reacted with the peptide in the presence of the
catalyst to form a red color compound, i.e. formazan, which wasm
AU
         40           45           50           55           60            65          70
es
2250
2000
1750
1500
1250
1000
750
500
250
0
-250
42
.7
83
FH-2
y of antihistamine-releasing peptide.
0.43
0.32
0.21
0.10
-0.01
0     10    20    30    40   50   60   70   80   90   100   110   120
Effluent (mL)
A
bs
or
ba
nc
e 
(22
0 n
m)
Figure 3. Gel ﬁltration chromatography of V. orientalis venom on G-25
Sephadex.
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Figure 4. RP-HPLC chromatogram of V. orientalis venom.
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Figure 5. RP-HPLC chromatogram of antihistamine-releasing peptide.
Table 1
Molecular masses, primary structures and identities of histamine releasing p
Number of b ions Peptide sequences Monoisotopic masses
1 I 114.091 93
2 IN 228.134 86
3 INL 341.218 92
4 INLK 469.313 89
5 INLKA 540.351 00
6 INLKAI 653.435 06
7 INLKAIA 724.472 18
8 INLKAIAA 795.509 29
9 INLKAIAAL 908.593 36
10 INLKAIAALV 1007.661 77
11 INLKAIAALVK 1135.756 73
12 INLKAIAALVKK 1263.851 69
13 INLKAIAALVKKV 1362.920 11
The full name of the peptide was mastoparan O.
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cytotoxic effect on mast cells, caused concentration dependent
increase in LDH and had an IC50 of 80 mmol/L on mast cells
(Figure 6).
3.5. Mast cell degranulation
The absorbance of different concentrations of the peptide
with adherent cells in microplate after overnight incubating was
read. The results showed the IC50 of mast cells degranulation
126 mmol/L, which was approximately high, implying that this
peptide had high selectivity for normal cells and had immuno-
modulation property which led the prevention of immune system
activation (Figure 7).eptide present in semi-preparative RP-HPLC fraction.
Number of y ions Peptide sequences Monoisotopic masses
1 V 118.086 85
2 KV 246.181 81
3 KKV 374.276 77
4 VKKV 473.345 19
5 LVKKV 586.429 25
6 ALVKKV 657.466 36
7 AALVKKV 728.503 48
8 IAALVKKV 841.587 54
9 AIAALVKKV 912.624 66
10 KAIAALVKKV 1040.719 62
11 LKAIAALVKKV 1153.803 68
12 NLKAIAALVKKV 1267.846 61
13 INLKAIAALVKKV 1380.930 67
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Figure 6. LDH activity on mast cells in presence of the peptide and 0.1%
Triton.
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Figure 7. The peptide degranulation activity on peritoneal mast cells.
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Avoiding mast cell degranulation and consequent histamine
release, immune system activation would be the goal of new
drug development. A constituent of bee venom named mast cell
degranulating (MCD) peptide has both anti-inﬂammatory and
inﬂammatory activities. Mizuno et al. showed that mastoparan
(5–30 mmol/L), a tetradecapeptide isolated from wasp venom,
caused histamine release from RBL-2H3 cells in a concentration
and time-dependent manner [17], whereas based on our results,
wasp venom peptide exhibited dissimilar effect, which has
previously been shown in bee venom [18]. On the other hand,
different kinds of mastoparan have shown histamine releasing
activity [19], which is in contrast with our ﬁndings explaining
the presence of different peptides with diverse activity in wasp
venom. Besides, more investigations showed that bee venom
contains several peptides with biological activity, and the
major known peptides are melittin and apamin with hemolytic
and neurotoxic activities respectively and a number of minor
peptides. The researchers showed anti-inﬂammatory property
just for mast cell degranulating peptide in bee venom [20].
Apamin, a small conductance Ca2+-activated K+ channel
blocker, signiﬁcantly inhibited both ovalbumins which induced
tracheal contraction and histamine release from lung tissues
[21]. The results of some investigations suggest that apamin
could reduce allergic airway inﬂammation by means of mast
cell stabilizing effect [22]. Apamin has also an anti-allergic ac-
tivity by inhibiting mast cells histamine releasing [22]. It is
claimed that the main reason of antihistamine-releasing effect
of this peptide is disulﬁde exchange bindings between its re-
ceptors and immunoglobulin E (IgE) on mast cell surface in a
dose–response manner which partially inhibits mast cell
degranulation [23]. Moreover, it has been found that mast cell
degranulating inhibition by this peptide could take place at
concentrations higher than those that would cause the release
of histamine and it might be because of its interaction with the
IgE molecule, which is associated with allergic reactions [24].
It was assumed that disulﬁde exchange between IgE and the
MCD peptide on the mast cell surface at high doses might
prevent the release of histamine, which would allow the MCD
peptide to act as an anti-allergic agent [22]. By contrast, our
peptide had no histamine releasing effects even on low doses.
The venom of the European honey bee (Apis mellifera) has
long been considered to be a rich source of anti-inﬂammatory
activities. To date, apitherapy has continued to be a common
practice in China, Eastern Europe and South America in
different types of inﬂammation and infection [20,24,25].
Cytotoxicity data from a LDH release assay, which measure
damage to the plasma membrane showed no signiﬁcant
increase in percentage of LDH release and its IC50 was nearly
128 mL, so we conﬁrmed that LDH absorbance was not
affected by this peptide. Taken together, the data strongly
suggest that 128 mL or lower peptide concentrations have no
cytotoxic action after incubation period. In another study, the
anti-inﬂammatory activities of peptide 401, contained 22 resi-
dues and occurred in the venom of the common European honey
bee, and compound 48/80 completely suppressed skin reactions
to the mast cell-derived amines. Pretreatment of rats with com-
pound 48/80 also suppressed the apparent anti-inﬂammatory
actions of peptide 401 and compound 48/80 [26]. These
ﬁndings would potentially conﬁrm the present study results
which claimed V. orientalis wasp venom contained bothinﬂammatory and anti-inﬂammatory peptide, and detection of
such peptide would be great goal in immune system disorder
treatment. Moreover, LDH assay strongly suggests that cell
death is not a mechanism by which isolated peptide from
V. orientalis inhibits mast cell degranulation.
Antihistamine-releasing activity of a peptide isolated from
V. orientalis wasp venom was shown in this study. This peptide
had no signiﬁcant effect on LDH release from mast cells, which
indicates that it would not cause cellular death on these cells.
This is an advantage for a peptide with potential medical use as
immune system of the host will not be activated.
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